Home » Stocks » AGLE

Aeglea Biotherapeutics, Inc. (AGLE)

Stock Price: $7.89 USD -0.09 (-1.13%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 378.22M
Revenue (ttm) n/a
Net Income (ttm) -79.67M
Shares Out 62.24M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $7.89
Previous Close $7.98
Change ($) -0.09
Change (%) -1.13%
Day's Open 8.07
Day's Range 7.81 - 8.22
Day's Volume 243,329
52-Week Range 3.51 - 11.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 weeks ago

AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benef...

Zacks Investment Research - 2 weeks ago

Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PRNewsWire - 1 month ago

AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inno...

PRNewsWire - 1 month ago

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inno...

PRNewsWire - 1 month ago

AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inno...

PRNewsWire - 2 months ago

AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inn...

Zacks Investment Research - 2 months ago

Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GuruFocus - 2 months ago

Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.

PRNewsWire - 2 months ago

AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as inn...

PRNewsWire - 3 months ago

AUSTIN, Texas, Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innov...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics ...

Zacks Investment Research - 4 months ago

Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics a...

Zacks Investment Research - 6 months ago

Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 6 months ago

Is (AGLE) Outperforming Other Medical Stocks This Year?

Forbes - 6 months ago

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...

Other stocks mentioned: DVAX, LQDA, PHAS, SEEL
Zacks Investment Research - 6 months ago

Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics

GlobeNewsWire - 7 months ago

AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as i...

GlobeNewsWire - 7 months ago

  Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis

Zacks Investment Research - 7 months ago

Is (AGLE) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Find Strong Stocks During the Coronavirus with New Analyst Coverage

Other stocks mentioned: SQNS, VRSN
Zacks Investment Research - 8 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: NJR, SQNS, VRSN
Zacks Investment Research - 8 months ago

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).

Zacks Investment Research - 8 months ago

Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 8 months ago

AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as s...

GlobeNewsWire - 8 months ago

AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as d...

GlobeNewsWire - 8 months ago

AUSTIN, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as ...

GlobeNewsWire - 9 months ago

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as s...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide so...

GlobeNewsWire - 1 year ago

Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9 Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9

GlobeNewsWire - 1 year ago

Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79%

GlobeNewsWire - 1 year ago

Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3

Seeking Alpha - 1 year ago

The stock has gained 15% during the past month due to insider buying.

GuruFocus - 1 year ago

President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 31,905 shares of AGLE on 06/14/2019 at an average price of $6.16 a share.

Zacks Investment Research - 1 year ago

Aeglea reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.

About AGLE

Aeglea BioTherapeutics, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degra... [Read more...]

Industry
Biotechnology
IPO Date
Apr 7, 2016
CEO
Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
AGLE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 15.63, which is an increase of 98.10% from the latest price.

Price Target
$15.63
(98.10% upside)
Analyst Consensus: Buy